Integer (NYSE:ITGR) Reaches New 1-Year High – Here’s Why

Shares of Integer Holdings Co. (NYSE:ITGR) reached a new 52-week high on Monday . The stock traded as high as $142.00 and last traded at $142.00, with a volume of 367 shares traded. The stock had previously closed at $138.11.

Analyst Ratings Changes

Several analysts have weighed in on ITGR shares. Benchmark lifted their price objective on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Truist Financial reduced their price target on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Bank of America increased their target price on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. KeyCorp upped their price objective on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Finally, Citigroup lifted their target price on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Integer has an average rating of “Moderate Buy” and an average target price of $139.75.

Integer Stock Performance

The company has a market cap of $4.67 billion, a P/E ratio of 42.63, a price-to-earnings-growth ratio of 1.98 and a beta of 1.09. The company’s 50-day moving average is $130.22 and its two-hundred day moving average is $123.57. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The company had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.27 earnings per share. Equities analysts predict that Integer Holdings Co. will post 5.34 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in Integer by 460.4% during the 2nd quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock worth $658,000 after acquiring an additional 4,636 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Integer by 3.0% during the 3rd quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock valued at $69,943,000 after buying an additional 15,446 shares in the last quarter. Earnest Partners LLC raised its stake in Integer by 3.2% during the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after buying an additional 37,340 shares during the last quarter. Great Lakes Advisors LLC boosted its stake in Integer by 56.7% in the 2nd quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider’s stock worth $5,236,000 after purchasing an additional 16,355 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Integer during the 3rd quarter valued at about $651,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.